Theravance Biopharma Inc (TBPH NASDAQ) stock market data APIs
$17.6639
0.16(0.9%)
as of December 10, 2025
Try our APIs with
free plan!
Theravance Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Prev. Close
17.6639
Open
17.8255
High
17.9914
Low
17.1457
52 wk Range
7.9-20.33
Market Cap
892 M
P/E Ratio
30.8947
Shares Outstanding
50 672 K
Revenue
80 327 K
EPS
0.0435
Beta
0.143
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Theravance Biopharma Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Theravance Biopharma Inc data using free add-ons & libraries
Get Theravance Biopharma Inc Fundamental Data
Theravance Biopharma Inc Fundamental data includes:
- Net Revenue: 80 327 K
- EBITDA: -31 164 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.1335
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Theravance Biopharma Inc News
New
Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Theravance Biopharma (TBPH). Shares have lost about 3.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continu...
Millrose Properties Stock Has Surged 48% Since February Debut — So Why Did One Investor Sell a $23 Million Stake?
Key Points New York City-based Newtyn Management sold 807,135 shares of Millrose Properties, reducing its position by $23 million in the third quarter. The transaction represented approximately 2.8% ...
Millrose Properties Stock Has Surged 48% Since February Debut — So Why Did One Investor Sell a $23 Million Stake?
Key Points New York City-based Newtyn Management sold 807,135 shares of Millrose Properties, reducing its position by $23 million in the third quarter. The transaction represented approximately 2.8% ...
Why One Investor Bought $67.5 Million in Array Digital Infrastructure Stock
Key Points New York City-based Newtyn Management added 1.35 million shares of Array Digital Infrastructure, an estimated $67.5 million trade based on quarterly average pricing. The position change re...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
